Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
about
Immunotherapy for head and neck cancer: latest developments and clinical potentialCD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasThe Role of Immunotherapy in Multiple MyelomaChimeric Antigen Receptors Modified T-Cells for Cancer TherapyCAR T Cell Therapy: A Game Changer in Cancer TreatmentDevelopment of Novel Immunotherapies for Multiple MyelomaExploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinicRedirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ TumorsThe role of SLAMF7 in multiple myeloma: impact on therapy.Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.Autologous lymphapheresis for the production of chimeric antigen receptor T cells.Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine.Differentiation stage of myeloma plasma cells: biological and clinical significance.Genome-Edited T Cell Therapies.Engineering cord blood to improve engraftment after cord blood transplant.Driving CAR T-cells forwardThe Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic MalignanciesOccurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma.Making Better Chimeric Antigen Receptors for Adoptive T-cell TherapyMolecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene TherapyMyeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapyPhase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.Carfilzomib boosted combination therapy for relapsed multiple myelomaPotent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins.Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell KillingImmunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.How do i participate in T-cell immunotherapy?Opportunities and challenges for the cellular immunotherapy sector: a global landscape of clinical trials.Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models.CAR T-cells merge into the fast lane of cancer care.Adoptive Cell Therapy in Multiple Myeloma.Novel Immunotherapies for Multiple Myeloma.Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).
P2860
Q26745428-5223CB67-2EDA-45FD-B446-0DB0DD5DED3FQ26749139-4E716DF3-7DFA-43A5-B081-51FF7B3DC49FQ26771144-1584725E-CD6B-4166-91C8-B88C2D5307F8Q26773309-E8CD8B77-80C5-4691-94D9-A1ECE807E927Q26822769-4023D290-2779-4429-9B9C-6FB2F1BD8FF8Q28066890-D27D3504-6A01-4357-9756-AB1DB2FA2E4EQ28075992-CB33F89C-FD26-4E5A-A02C-883011B21E37Q28553650-C0A1294A-CD4B-4CD0-91D0-593470B9276EQ30249167-4D1A867E-8634-4146-BB1E-53827C8623ECQ30252944-3A7D7292-7C1F-42FE-B5E6-BBDC1571572EQ30253090-15AB8EC9-C5EB-4D6B-A87E-D3B322ADC8F6Q30830664-BFB6A11E-FCD7-4D4F-BBEA-8ADB5E52B37CQ33712516-DF45DA3A-A7F7-4EBF-B97B-2F639323E8D3Q33729598-99711753-1EB8-4772-8618-6C0DC03BBB0AQ33766995-23888FE8-52FB-46E4-BB94-B611C298D9CCQ34046505-76ADC92F-BC93-4A34-88DA-A52FB833BC6DQ36547199-85188C21-C75A-4FCC-8BB6-495EC25C8DAEQ36754816-9AB078D8-D1DE-4CC0-91AE-5416323ABD44Q36830759-B05B06F6-2365-4A5B-8750-2616F5C3A03BQ36928580-C4179350-EE94-4660-9F08-A0D24FA3A458Q36982805-555CE5FE-8D4D-45A6-9B5F-14B406A35252Q37117624-D39A8C64-4AFF-49BF-B0DE-3D676504544AQ37217432-A3CAC4EE-F832-4308-946F-DE577E33ADCFQ37517482-03D69743-8E9A-47D2-A7BC-C4929D7BC481Q37588329-16FB9EDD-EAF9-4C89-93CF-7BBB3A12A136Q37609801-A30752D7-5DA6-4CB6-B2D8-40B9134BA27DQ37652953-5540967F-9770-43A7-A4D3-F9E4B2F7741BQ37687119-B9E362F8-BF12-4345-A7FE-150FD842454FQ37710498-D8CCF029-FBE5-4F3A-8376-F4F948D33C80Q37722551-6B93A08D-FBF0-4A5E-A4EF-DE325C8A7997Q38371637-13A18976-D499-48F5-AD00-3611FCDB73D5Q38604100-E79D6A14-4A12-4F7D-9973-16B29C03160FQ38612233-31FCF632-0349-4BCD-8451-F36AC788131CQ38616707-BA6355A9-0DA5-4844-A501-31D98F223273Q38635027-F89A4B91-2791-4134-BA2B-0F92D577F065Q38635138-F9869D56-B099-471C-B843-3E842A6153BFQ38640444-D9FCFD55-FA71-4BB6-A998-BF6E57C59962Q38666256-CB003D4B-7938-4BFF-A399-8DD91992540CQ38672091-E6CC43B2-5FA6-4BAA-9F0F-83BA3AF48088Q38688055-9D92201D-1C9C-4BCD-8C1A-5CE07DEB9BEC
P2860
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
@ast
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
@en
type
label
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
@ast
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
@en
prefLabel
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
@ast
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
@en
P2093
P2860
P50
P356
P1476
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
@en
P2093
Brendan M Weiss
Bruce L Levine
Carl H June
Dan T Vogl
Edward A Stadtmauer
J Joseph Melenhorst
Karen Dengel
Naseem D S Kerr
Simon F Lacey
P2860
P304
P356
10.1056/NEJMOA1504542
P407
P577
2015-09-01T00:00:00Z